Casey Woodring
Stock Analyst at JP Morgan
(1.17)
# 3,802
Out of 5,138 analysts
58
Total ratings
36.36%
Success rate
-10.14%
Average return
Main Sectors:
Stocks Rated by Casey Woodring
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEM Tempus AI | Maintains: Neutral | $85 → $80 | $66.78 | +19.80% | 1 | Dec 15, 2025 | |
| NTRA Natera | Maintains: Overweight | $250 → $260 | $234.85 | +10.71% | 3 | Dec 15, 2025 | |
| ILMN Illumina | Maintains: Neutral | $105 → $130 | $147.17 | -11.67% | 2 | Dec 15, 2025 | |
| GH Guardant Health | Maintains: Overweight | $90 → $120 | $114.87 | +4.47% | 2 | Dec 15, 2025 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $165 → $190 | $218.19 | -12.92% | 10 | Dec 15, 2025 | |
| BRKR Bruker | Maintains: Overweight | $50 → $55 | $49.84 | +10.35% | 1 | Dec 15, 2025 | |
| BLLN BillionToOne | Maintains: Overweight | $150 → $145 | $85.95 | +68.70% | 2 | Dec 10, 2025 | |
| A Agilent Technologies | Maintains: Overweight | $165 → $180 | $135.83 | +32.52% | 2 | Nov 25, 2025 | |
| QDEL QuidelOrtho | Maintains: Underweight | $26 → $22 | $32.73 | -32.78% | 5 | Nov 7, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $13 → $15 | $22.05 | -31.97% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $18.69 | -14.39% | 3 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $12 | $11.85 | +1.27% | 1 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $177 → $255 | $233.69 | +9.12% | 1 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $78 | $75.11 | +3.85% | 6 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $300 → $325 | $383.86 | -15.33% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $600 → $650 | $619.01 | +5.01% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,200 → $1,285 | $1,403.58 | -8.45% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $265 → $150 | $176.57 | -15.05% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $53 | $55.45 | -4.47% | 4 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $6 | $2.59 | +131.66% | 3 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $25 → $23 | $22.50 | +2.22% | 2 | Oct 31, 2023 |
Tempus AI
Dec 15, 2025
Maintains: Neutral
Price Target: $85 → $80
Current: $66.78
Upside: +19.80%
Natera
Dec 15, 2025
Maintains: Overweight
Price Target: $250 → $260
Current: $234.85
Upside: +10.71%
Illumina
Dec 15, 2025
Maintains: Neutral
Price Target: $105 → $130
Current: $147.17
Upside: -11.67%
Guardant Health
Dec 15, 2025
Maintains: Overweight
Price Target: $90 → $120
Current: $114.87
Upside: +4.47%
Charles River Laboratories International
Dec 15, 2025
Maintains: Neutral
Price Target: $165 → $190
Current: $218.19
Upside: -12.92%
Bruker
Dec 15, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $49.84
Upside: +10.35%
BillionToOne
Dec 10, 2025
Maintains: Overweight
Price Target: $150 → $145
Current: $85.95
Upside: +68.70%
Agilent Technologies
Nov 25, 2025
Maintains: Overweight
Price Target: $165 → $180
Current: $135.83
Upside: +32.52%
QuidelOrtho
Nov 7, 2025
Maintains: Underweight
Price Target: $26 → $22
Current: $32.73
Upside: -32.78%
10x Genomics
Nov 7, 2025
Maintains: Neutral
Price Target: $13 → $15
Current: $22.05
Upside: -31.97%
Nov 5, 2025
Maintains: Neutral
Price Target: $14 → $16
Current: $18.69
Upside: -14.39%
Oct 30, 2025
Downgrades: Neutral
Price Target: $14 → $12
Current: $11.85
Upside: +1.27%
Oct 29, 2025
Maintains: Overweight
Price Target: $177 → $255
Current: $233.69
Upside: +9.12%
Oct 22, 2025
Downgrades: Neutral
Price Target: $78
Current: $75.11
Upside: +3.85%
Oct 9, 2025
Maintains: Neutral
Price Target: $300 → $325
Current: $383.86
Upside: -15.33%
Oct 9, 2025
Maintains: Overweight
Price Target: $600 → $650
Current: $619.01
Upside: +5.01%
Oct 9, 2025
Maintains: Neutral
Price Target: $1,200 → $1,285
Current: $1,403.58
Upside: -8.45%
Apr 29, 2025
Downgrades: Neutral
Price Target: $265 → $150
Current: $176.57
Upside: -15.05%
Jun 18, 2024
Maintains: Overweight
Price Target: $51 → $53
Current: $55.45
Upside: -4.47%
May 13, 2024
Maintains: Neutral
Price Target: $7 → $6
Current: $2.59
Upside: +131.66%
Oct 31, 2023
Maintains: Neutral
Price Target: $25 → $23
Current: $22.50
Upside: +2.22%